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SUMMARY
Thyroid storm is a rare and life-threatening state of
thyroid hormone excess. Rapid recognition of thyroid
storm is key to decreasing the morbidity and mortality of
this condition. Clinical manifestations of thyroid storm
include unexplained weight loss, hyperactivity and
irritability. The most common causes of thyrotoxicosis are
Graves’ disease, toxic multinodular goitre and toxic
adenoma. We present a rare case of thyroid storm
induced by dual nivolumab and ipilimumab
immunotherapy in a patient receiving treatment for
advanced melanoma. In this case, our patient was
admitted for thyroid storm 1 month after initiating
treatment with nivolumab and ipilimumab
immunotherapy. The patient was treated with β-blockers,
antithyroid medications and systemic steroids resulting in
an improvement in thyroid function testing and
symptoms.
BACKGROUND
Novel immunotherapy agents, nivolumab and ipili-
mumab, have the capacity to effectively destroy
immunogenic tumours such as melanoma through
the use of immune checkpoints.1–3 Immune-check-
point inhibitor therapies are evolving to be the
mainstay of therapy in BRAF-mutated advanced
melanoma.4 Ipilimumab is a monoclonal antibody
against CTLA-4, boosting T-cell activation and pro-
liferation.5 Nivolumab is a human programmed
death receptor-1 (PD-1) blocking antibody, which
also creates a negative regulatory T-cell response.6
Through the use of alternative checkpoints, these
agents provide distinct clinical activity in treatment
of advanced melanoma compared with monother-
apy, as highlighted by Wolchock et al.4 Owing to
T-cell activation throughout the body, these agents
can cause various autoimmune adverse reactions
including immune–mediated pneumonitis, immune-
mediated colitis, immune-mediated hepatitis,
immune-mediated hyperthyroidism and immune-
mediated hypothyroidism.5 6 In nivolumab and ipi-
limumab drug trials, hyperthyroidism occurred in
8% (34/407) of patients.5 6 Four of these patients
had grade 3 hyperthyroidism and the rest of the
patients had grade 1 or grade 2 hyperthyroidism.5 6
We present a rare case of thyroid storm in a patient
with advanced melanoma receiving dual nivolumab
and ipilimumab therapy.
CASE PRESENTATION
A 24-year-old Caucasian woman with a history of
metastatic melanoma presented to the emergency
department, with a 3-day history of intractable
nausea, vomiting and anxiety.
She had been initiated on dual nivolumab and
ipilimumab therapy 1 month prior and received
two courses of therapy thus far. Her last dose was
1 week prior to presentation. She had previously
completed 1 year of high-dose interferon therapy.
Surgical history included right video-assisted thora-
coscopic surgery with right lower lobe wedge resec-
tion due to metastasis 6 weeks prior and right
cheek melanoma resection 2 years prior. Medical
history included depression and anxiety. The
patient’s medications included atenolol, citalopram
and alprazolam. She denied alcohol or illicit drug
use. On presentation, she was febrile to 40.3°C
(104.5° Fahrenheit), tachycardic to 146 bpm, and
agitated with symptoms of nausea and vomiting.
Her blood pressure was stable at 138/87. Her
Glasgow coma scale was 15. On examination, the
patient was agitated and acutely anxious but still
awake, alert and oriented. She was diaphoretic and
flushed with no jugular venous distention, no per-
ipheral oedema, and with regular rate and rhythm
on cardiac examination, and clear breath sounds on
lung examination. The rest of the physical examin-
ation was unremarkable. Most notably, neither
thyromegaly, nor exophthalmos, nor tender thyroid
was appreciable on physical examination. On the
Burch et al diagnostic point scale for thyroid storm,
our patient scored 85. By this scoring system, a
score higher than 45 is suggestive of thyroid
storm.1 The patient was admitted to the intensive
care unit (ICU), with endocrinology and oncology
consultation.
INVESTIGATIONS
Initial complete blood count, basic metabolic panel,
lipase and urinalysis were all normal. Urine preg-
nancy test was negative. Blood cultures were
obtained and negative at 48 h. An ECG showed
sinus tachycardia. The patient’s thyroid function
tests on the day of presentation were: thyroid
stimulating hormone 0.062 mU/mL, free thyroxine
4.0 ng/dL and free triiodothyronine 6.4 ng/dL
(normal range 1.5–3.5 ng/dL). Her historical
thyroid function tests after receiving interferon
therapy but prior to initiation of treatment with
nivolumab and ipilimumab were: thyroid stimulat-
ing hormone 3.289 mU/mL and free thyroxine
0.7 ng/dL. Thyroid peroxidase and thyroid stimu-
lating immunoglobulin levels were within normal
range.
A thyroid ultrasound revealed diffuse thyroid
heterogeneity consistent with non-specific thyroidi-
tis. Radioactive iodine uptake study was not per-
formed due to the patient having had a recent CT
scan with intravenous contrast. Chest X-ray (CXR)
was negative.
McMillen B, et al. BMJ Case Rep 2016. doi:10.1136/bcr-2016-214603 1
Findings that shed new light on the possible pathogenesis of a disease or an adverse effect
The patient improved symptomatically from her initial pres-
entation and was discharged home the next day from the inten-
sive care unit (ICU).
The patient returned to the emergency department within
24 h of initial discharge with re-emergence of her symptoms
including nausea, vomiting, agitation and anxiety. She was
febrile to 38.9°C (102° Fahrenheit) with tachycardia to 120. All
other vital signs were stable. Physical examination remained
non-focal. A chest X-ray, urinalysis, basic metabolic panel and
complete blood count with differential were unremarkable.
Repeat thyroid stimulating hormone was 0.043 mU/mL. Free
thyroxine improved to 2.1 ng/dL. On the Burch et al diagnostic
point scale for thyroid storm, our patient scored 65.
The patient was admitted to the progressive care unit for con-
cerns of unresolved thyroid storm, with endocrinology and
oncology consultation. Investigations were broadened to include
a thorough infectious work up that included lactate within
normal limits, a negative respiratory viral panel, a negative rapid
streptococcus, negative urine gonorrhoea and negative chla-
mydia PCR. Lumbar puncture was performed and resultant
Gram stain, culture, cell count, protein and glucose were all
normal. Infectious disease was consulted. Cryptococcal antigen,
Clostridium difficile assay, cytomegalovirus antigen, histoplasma
antigen, HIV and mono heterophile antibody all resulted nega-
tive. Final blood and urine culture results were negative. Repeat
blood cultures were negative at 48 h. Urine culture was negative.
CT of the chest with intravenous contrast revealed no acute
process, most notably no pulmonary embolism.
DIFFERENTIAL DIAGNOSIS
The patient had signs and symptoms of thyroid storm based on
the diagnostic criteria for thyroid storm developed by Burch
et al, including agitation, nausea with vomiting, tachycardia,
fever and a known history precipitant of ipilimumab and nivolu-
mab treatment.1 The differential diagnoses were broad on initial
presentation. They included medication-induced thyroid storm,
Graves’ disease, thyroiditis, thyroid adenoma, toxic multinodular
goitre and Hashimoto’s thyroiditis. Interferon-induced thyroid
dysfunction was less likely given normal thyroid function tests
after completion of therapy. Graves’ disease was less likely as
thyroid-stimulating immunoglobulins were within normal range
and the patient was without exophthalmos. Hashimoto’s thyroi-
ditis was less likely as thyroid peroxidase immunoglobulins were
within normal range. Thyroid ultrasound with Doppler showed
neither adenoma nor goitre (figure 1). Therefore, the most likely
diagnosis was immune-mediated thyroiditis with resultant thyro-
toxicosis with precipitation of thyroid storm. This was
additionally supported after the trend of thyroid function tests
before and after the initiation of nivolumab and ipilimumab
immunotherapy was examined (figure 2).
TREATMENT
The patient, on initial admission to the ICU for thyroid storm,
was initiated on propranolol 60 mg every 6 h to achieve
adequate control of her heart rate, and hydrocortisone 100 mg
every 8 h. This is slightly under the recommended steroid dose
of 1 mg/kg of prednisone, or equivalent, daily, as suggested by
the risk evaluation and mitigation strategy (REMS) for treatment
of an immune-mediated adverse reaction induced by ipilimu-
mab.7 The patient was also started on methimazole 20 mg every
8 h based on the drug manufacture’s dosing recommendations.
On day 2, the methimazole was discontinued as the patient’s
white cell count trended downwards raising concern for agran-
ulocytosis. She was then started on cholestyramine to help bind
and excrete excess thyroid hormone. She was discharged from
the ICU on a medication regimen including cholestyramine 4 g
three time a day, hydrocortisone 25 mg two times a day and
propranolol 60 mg every 6 h. Minimal steroid dosing on dis-
charge was recommended based on the concern that an elevated
steroid dosing would counteract the immunotherapy.
On her second admission, the patient was continued on
hydrocortisone 25 mg two times a day. She was started on
empiric antibiotics including vancomycin and meropenem after
48 h of unresolved fever and intermittent tachycardia.
Antibiotics were discontinued after 24 h of the patient becoming
afebrile and after negative infectious work up. She was transi-
tioned to oral prednisone 80 mg daily at the time of discharge.
OUTCOME AND FOLLOW-UP
Five weeks after discharge, the patient’s thyroid function tests
improved: thyroid stimulating hormone was 0.951 mU/mL and
free thyroxine was 0.8 ng/dL. She was euthyroid and only
reporting of fatigue. She remained on high-dose prednisone
therapy with plans to taper the dose.
DISCUSSION
This case report is an example of dual nivolumab and ipilimu-
mab immunotherapy causing an immune-mediated
Figure 1 Thyroid ultrasound (US) of our patient during her second
admission over the right thyroid lobe showing diffuse thyroid
heterogeneity consistent with non-specific thyroiditis.
Figure 2 Thyroid function tests obtained over time during our
patient’s treatment course. Day 0 represents baseline thyroid function
tests prior to initial cycle of immunotherapy. Day 21 represents thyroid
function tests on day of second cycle. Day 25 represents day of initial
presentation of first hospitalisation. Day 28 represents day of
presentation of her second hospitalisation.
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thyrotoxicosis, precipitating thyroid storm. Thyroid storm is a
clinical diagnosis, but the point scale system developed by Burch
et al can aid in confirming the diagnosis. This scale system
assigns points in the categories of thermoregulatory dysfunction,
central nervous system effects, gastrointestinal-hepatic dysfunc-
tion, cardiovascular dysfunction and precipitant history. Scores
are totalled and a score of 45 or greater is highly suggestive of
thyroid storm.1 Our patient’s score totalled 85 on initial presen-
tation and 65 on readmission.
It is important to point out that our patient was treated with
interferon for 1 year prior to the initiation of nivolumab and
ipilimumab. Interferon has also been implicated in causing
thyroid dysfunction. However, our patient had thyroid function
testing that was within normal range prior to the initiation of
nivolumab and ipilimumab.
A database search for ‘nivolumab and ipilimumab thyrotoxi-
cosis’ revealed one case report where ipilimumab alone caused
thyroid storm in a patient receiving immunotherapy for
melanoma. In that case, antithyroid medications were started
with resolution of symptoms. Steroids were considered, but not
started because of oncologic concern for reversal effects of the
patient’s immunotherapy.8
Individual clinical drug trials of nivolumab and ipilimumab
do not mention any cases of thyroid storm. Prescribing informa-
tion does recommend monitoring thyroid function tests prior to
and periodically during the course of treatment and medically
managing adverse outcomes. There is currently no dose adjust-
ment in the event of thyroid dysfunction and no dose recom-
mendation for corticosteroid administration in the event of an
adverse reaction.5 6 The recommended steroid dose of 1 mg/kg
of prednisone, or equivalent, daily, is suggested by the REMS
for treatment of an immune-mediated adverse reaction induced
by ipilimumab.7
In conclusion, we present a rare case of nivolumab-induced
and ipilimumab-induced thyroid storm.
Prompt recognition of thyroid storm and initiation of high-
dose steroids in our patient was important in preventing pos-
sible morbidity and mortality. Early tapering of steroid therapy
due to concern about steroids counteracting immunotherapy in
the setting of life-threatening malignant melanoma was poten-
tially responsible for the incomplete resolution of the thyroid
storm seen on readmission. Our patient improved after
re-initiation of high-dose steroid therapy with a slow taper.
However, long-term outcomes are still questionable at this point
given her adverse response to these novel agents.
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Learning points
▸ Nivolumab and ipilimumab therapy shows great promise in
improving the prognosis for patients with advanced
melanoma, but providers should be mindful that this therapy
may be linked to immune-related adverse events such as
thyrotoxicosis and thyroid storm.
▸ Thyroid function tests and thyroid symptoms should be
monitored in patients with metastatic melanoma undergoing
nivolumab and ipilimumab immunotherapy.
▸ Prompt recognition of thyroid storm is potentially life-saving.
However, the clinical diagnosis is challenging given the
non-specific signs and symptoms. Tools such as the Burch
et al point scale for the diagnosis of thyroid storm can be
helpful as it attributes points for thermoregulatory
dysfunction, central nervous system effects,
gastrointestinal-hepatic dysfunction, cardiovascular
dysfunction and precipitant history. Scores are totalled and a
score of 45 or greater is highly suggestive of thyroid storm.1
▸ Prompt treatment of thyroid storm is potentially life-saving.
Close monitoring in an inpatient setting in addition to
treatment with β-blockers, antithyroid agents, steroids and
bile sequestering therapies are recommended. Endocrinology
consultation is also beneficial.
▸ Thyroid storm induced by dual nivolumab and ipilimumab
treatment may require high-dose steroid therapy based on
the existing recommendations to treat immune-mediated
adverse reactions with 1 mg/kg of prednisone or equivalent.7
However, it is unclear if this is too high of a dose in the
setting of its potential interaction with the immunotherapy.
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